



Porphyromonas gulae Activates Unprimed and Gamma Interferon-Primed Macrophages via the Pattern Recognition Receptors Toll-Like Receptor 2 (TLR2), TLR4, and NOD2

James A. Holden,^a Neil M. O'Brien-Simpson,^a Jason C. Lenzo,^a Rebecca K. H. Orth,^a Ashley Mansell,^b Eric C. Reynolds^a

Oral Health CRC, Melbourne Dental School, Bio21 Institute, The University of Melbourne, Melbourne, Australia^a; Centre for Innate Immunity and Infectious Disease, Monash Institute of Medical Research, Monash University, Clayton, Australia^b

ABSTRACT *Porphyromonas gulae* is an anaerobic, Gram-negative coccobacillus that has been associated with periodontal disease in companion animals. The aims of this study were to analyze the ligation of pattern recognition receptors by *P. gulae* and the subsequent activation of macrophages. Exposure of HEK cells transfected with Toll-like receptors (TLRs) or NOD-like receptors to *P. gulae* resulted in the ligation of TLR2, TLR4, and NOD2. The effects of this engagement of receptors were investigated by measuring the synthesis of nitric oxide (NO), CD86 expression, and inflammatory cytokine production by wild-type, TLR2^{-/-}, and TLR4^{-/-} macrophages. The addition of *P. gulae* to unprimed and gamma interferon (IFN- γ)-primed (M1 phenotype) macrophages significantly increased the surface expression of CD86, but only M1 macrophages produced nitric oxide. *P. gulae*-induced expression of CD86 on unprimed macrophages was dependent on both TLR2 and TLR4, but CD86 expression and NO production in M1 macrophages were only TLR2 dependent. *P. gulae* induced an increase in secretion of interleukin-1 α (IL-1 α), IL-1 β , IL-6, IL-12p70, IL-13, tumor necrosis factor alpha (TNF- α), granulocyte colony-stimulating factor (G-CSF), monocyte chemoattractant protein 1 (MCP-1), and macrophage inflammatory protein 1 α (MIP-1 α) by M1 macrophages compared to that by unprimed controls. Among these cytokines, secretion of IL-6 and TNF- α by M1 macrophages was dependent on either TLR2 or TLR4. Our data indicate that TLR2 and TLR4 are important for *P. gulae* activation of unprimed macrophages and that activation and effector functions induced in M1 macrophages by *P. gulae* are mainly dependent on TLR2. In conclusion, *P. gulae* induces a strong TLR2-dependent inflammatory M1 macrophage response which may be important in establishing the chronic inflammation associated with periodontal disease in companion animals.

KEYWORDS periodontal disease, companion animals, *Porphyromonas gulae*, pattern recognition receptors

Companion animals, such as dogs and cats, are susceptible to periodontal disease, a chronic inflammatory disease of the tissues supporting the teeth (1). Severe forms of the disease involve destruction of the supporting tissues, including alveolar bone, eventually leading to tooth loss (2). In humans, the black-pigmented bacterium *Porphyromonas gingivalis* has been shown to be associated with the onset and progression of chronic periodontitis, a severe form of the disease. In companion animals (dogs and cats), the incidence of periodontal disease has been shown to increase with age, and in a North American study, 82% of dogs aged 6 to 8 years old had disease (3).

Received 20 April 2017 Returned for modification 24 May 2017 Accepted 13 June 2017

Accepted manuscript posted online 19 June 2017

Citation Holden JA, O'Brien-Simpson NM, Lenzo JC, Orth RKH, Mansell A, Reynolds EC. 2017. *Porphyromonas gulae* activates unprimed and gamma interferon-primed macrophages via the pattern recognition receptors Toll-like receptor 2 (TLR2), TLR4, and NOD2. Infect Immun 85:e00282-17. <https://doi.org/10.1128/IAI.00282-17>.

Editor Beth McCormick, University of Massachusetts Medical School

Copyright © 2017 American Society for Microbiology. All Rights Reserved.

Address correspondence to Eric C. Reynolds, e.reynolds@unimelb.edu.au.

J.A.H. and N.M.O.-S. contributed equally to this article.

Of the bacteria isolated from subgingival plaque from companion animals, three *Porphyromonas* species are most frequently isolated from dogs with periodontal disease: *Porphyromonas gulae*, *Porphyromonas salivosa*, and *Porphyromonas denticanis* (4–7). Of these, *P. gulae* has been shown to be present in 92% of animals with periodontitis (1). *P. gulae* is an anaerobic, Gram-negative coccobacillus that exhibits some biochemical and antigenic similarities to *P. gingivalis* (5, 7–9). Although *P. gulae* is commonly isolated from dogs with periodontal disease, the disease in companion animals most likely is similar to that in humans, in that it is a polymicrobial disease in which *Porphyromonas* spp. play an important, immune-dysregulating function (10). Furthermore, we previously showed that of several *Porphyromonas* species isolated from companion animals with periodontal disease, only *P. gulae* possesses arginine- and lysine-specific proteinases similar to the key virulence factors of *P. gingivalis* (11). This finding is consistent with *P. gulae* playing an important role in the initiation and progression of periodontal disease in companion animals.

Dogs are commonly used as animal models of human periodontal disease, using either the ligature model or infection with *P. gingivalis* (12). However, limited information is available concerning the interactions between immune cells and companion animal periodontal pathogens, such as *P. gulae*. In humans, chronic periodontitis is characterized by an inflammatory cell infiltrate of the gingival tissue, in which macrophages are a significant component (13). Furthermore, macrophages are often associated with other chronic inflammatory conditions, indicating that they play an important role in initiating and sustaining inflammation (14, 15). Therefore, the interaction of pathogens with macrophages is an important area of investigation to understand the induction of inflammation in periodontitis.

Inflammation typically begins after interaction of host innate immune cells, such as resident tissue macrophages, with pathogen-associated molecular patterns (PAMPs) via pattern recognition receptors (PRRs), such as NOD-like receptors (NLRs) or Toll-like receptors (TLRs). Ligation of TLRs on the macrophage surface by bacterial PAMPs, such as lipopolysaccharide (LPS) or lipoproteins, leads to macrophage activation (16). This activation results in the upregulation of antimicrobial compounds, increased antigen presentation capacity, and secretion of proinflammatory cytokines and chemokines. There have been limited studies regarding the interaction of *P. gulae* with cells of the innate immune system, such as macrophages, and no research, to date, has investigated the activation of individual TLRs. Recent research into macrophage activation has focused on the phenotypes developed during disease as a result of the cytokine environment at the time of activation (17, 18).

The presence of gamma interferon (IFN- γ), an important cytokine present during chronic inflammatory diseases, during macrophage activation polarizes macrophages toward an M1 phenotype (pre-M1-M ϕ), and when these cells are exposed to LPS, they mature into classically activated M1 macrophages (M1-M ϕ) (19). These macrophages exhibit greater antibacterial features than those of unprimed macrophages, increasing production of microbicidal compounds, such as nitric oxide. Classical inflammatory macrophages also have a greatly increased antigen presentation capacity, with increased expression of major histocompatibility complex (MHC) class II molecules and CD86, both of which are required for the initiation of an adaptive immune response.

We recently showed that *P. gulae* exposure activates mouse macrophages to produce interleukin-1 α (IL-1 α) and tumor necrosis factor alpha (TNF- α) at concentrations equivalent to those seen with *P. gingivalis* W50 but induces significantly higher concentrations of IL-6 (11). Here we characterize the PRR molecules with which *P. gulae* interacts and analyze how that PRR activation affects macrophage maturation.

RESULTS

***Porphyromonas gulae* activates transfected HEK cells through TLR2, TLR4, and NOD2.** The ligation of TLRs on immune cells is essential for induction of an immune response against pathogens. The activation of different TLRs and NOD receptors by *P. gulae* was investigated using HEK-Blue cells transfected with either NOD1, NOD2, TLR2,




FIG 1 TLR activation by *Porphyromonas gulae* whole cells. HEK-Blue cells transfected with the pattern recognition receptor NOD2 (a), TLR2 (b), or TLR4 (c) (2×10^4 cells/well) were incubated with *P. gulae* whole cells at various MOI for 2 h and then washed with DMEM containing antibiotics. After 24 h, the amount of alkaline phosphatase secreted into the medium was measured as a direct correlation of NF- κ B phosphorylation. The assay was repeated twice on each of three biological replicates ($n = 6$). HEK-Blue cells expressing NOD1, TLR5, TLR7, TLR8, or TLR9 were also tested but did not respond to whole *P. gulae* cells.

TLR4, TLR5, TLR7, TLR8, or TLR9 as a surface receptor, which if ligated activated NF- κ B phosphorylation, resulting in secretion of alkaline phosphatase. HEK-Blue cells were incubated with *P. gulae* whole cells at various multiplicities of infection (MOI) for 20 h, and then the accumulation of alkaline phosphatase in the medium was analyzed by combining the medium with HEK-Blue detection medium.

P. gulae induced the phosphorylation of NF- κ B in HEK-Blue cells transfected with TLR2, TLR4, or NOD2 (Fig. 1). No other TLRs or NOD receptors were activated at a significant level (data not shown). HEK-Blue (Null1; untransfected) cells were used as a control for endogenous TLRs and NOD receptors and were not activated by *P. gulae* or any TLR or NOD ligand (Fig. 1).

***Porphyromonas gulae* increases the expression of CD86 on M0 and M1 macrophages.** As TLR ligation is an essential step in macrophage maturation, the overall

activation state of macrophages incubated with *P. gulae* was analyzed by the cell surface expression of CD86, which we have shown in previous studies to be strongly upregulated in activated macrophages, along with CD80, CD40, and MHC class II activation markers (20). CD86 expression was measured by flow cytometry on C57/BL6 (wild type [WT]) immortalized macrophages (iMACs), TLR2 knockout (TLR2^{-/-}) iMACs, TLR4 knockout (TLR4^{-/-}) iMACs, or NOD2 knockdown iMACs after incubation with *P. gulae* and control TLR ligands. The experiment was performed on unprimed M0-M ϕ and IFN- γ -primed pre-M1-M ϕ . *Escherichia coli* LPS (TLR4 ligand) and Pam3CSK4 (TLR2 ligand) were used as TLR activation controls. Following *P. gulae* and TLR ligand incubation, macrophages were stained with anti-mouse CD86-phycoerythrin (PE)-Cy7 antibody and analyzed by flow cytometry. *P. gulae* and both TLR ligands induced significant ($P < 0.05$) increases in CD86 expression on unprimed WT M0-M ϕ (Fig. 2a). *P. gulae*-induced expression of CD86 was completely abrogated on TLR2^{-/-} and TLR4^{-/-} unprimed M0-M ϕ (Fig. 2c and e). Reducing the expression of NOD2 on naive iMACs through small interfering RNA (siRNA) interference did not appreciably decrease the expression of CD86 (Fig. 2g).

Priming with IFN- γ to generate a pre-M1-M ϕ phenotype resulted in significantly higher levels of CD86 expression than those on unprimed M0-M ϕ , and incubation with *P. gulae* significantly ($P < 0.05$) increased CD86 expression compared to that on the pre-M1-M ϕ controls (Fig. 2b). CD86 expression on TLR4^{-/-} but not TLR2^{-/-} M1-M ϕ was significantly ($P < 0.05$) increased upon incubation with *P. gulae* compared to that of controls (Fig. 2d and f). Reducing the expression of NOD2 on M1 iMACs through siRNA interference did not appreciably decrease the expression of CD86 (Fig. 2h). Although the TLR4^{-/-} macrophages exposed to *P. gulae* had less CD86 expression than that of the WT iMACs, the level of induction by the positive-control Pam3CSK4 ligand was correspondingly lower, indicating a lower overall responsiveness of these cells. The TLR2^{-/-} and TLR4^{-/-} iMACs showed increased expression only when they were incubated with *E. coli* LPS and Pam3CSK4, respectively, indicating the TLR specificity of the knockout iMACs.

***Porphyromonas gulae* induces nitric oxide production in macrophages.** Since *P. gulae* was able to induce the upregulation of CD86 in macrophages, functional assays were performed to quantify that activation. The ability of macrophages to produce nitric oxide in response to bacterial infection is essential for the bactericidal function of macrophages. Nitric oxide production was measured in WT, TLR2^{-/-}, and TLR4^{-/-} iMACs. The experiment was performed on unprimed M0-M ϕ and IFN- γ -treated pre-M1-M ϕ .

P. gulae was found not to induce nitric oxide production in unprimed M0-M ϕ , whereas the control TLR ligands *E. coli* LPS and Pam3CSK4 induced strong and TLR-specific responses (Fig. 3a, c, and e). However, M1-M ϕ (IFN- γ -treated pre-M1-M ϕ) incubated with *P. gulae* produced significantly ($P < 0.05$) larger amounts of nitric oxide than those in controls (Fig. 3b). The control TLR ligands induced significantly higher levels of nitric oxide than those induced by *P. gulae*; however, this could be attributed to the purity of the control ligands. TLR4^{-/-} but not TLR2^{-/-} M1-M ϕ produced significantly ($P < 0.05$) larger amounts of nitric oxide upon incubation with *P. gulae* than those seen with controls (Fig. 3d and f). The TLR2^{-/-} and TLR4^{-/-} iMACs responded only to *E. coli* LPS and Pam3CSK4, respectively, indicating that the cells were functioning correctly.

Production of cytokines and chemokines by M0 and M1 polarized macrophages after incubation with *P. gulae*. The maturation of M1 macrophages is characterized by the production of cytokines and chemokines which promote chronic inflammation. To investigate the cytokine response induced by *P. gulae*, we determined the concentrations of cytokines in the cell-free supernatants of WT, TLR2^{-/-}, and TLR4^{-/-} M1-M ϕ after incubation with *P. gulae* and TLR ligands by using a 23-plex Bioplex assay. Of the 23 cytokines and chemokines analyzed in the culture supernatant, only 14 (IL-1 α , IL-1 β , IL-6, IL-10, IL-12p70, IL-13, IL-17, TNF- α , KC, granulocyte colony-




FIG 2 Expression of CD86 on macrophages after exposure to *Porphyromonas gultae* whole cells. WT iMACs, TLR2^{-/-} iMACs, and TLR4^{-/-} iMACs (10⁵ cells) were incubated overnight with or without IFN-γ to prime the M1 macrophage phenotype or to give unprimed M0-Mφ, respectively. The unprimed and M1-primed macrophages were then incubated with viable *P. gultae* (MOI of 180:1) for 2 h and washed with DMEM containing antibiotics. *E. coli* LPS and Pam3CSK4 were used as TLR4 and TLR2 control ligands, respectively. The negative control was macrophages that were not incubated with TLR ligands or *P. gultae* cells. After 24 h, the level of CD86 expression was measured by flow cytometry. Data are expressed as percentages of CD86-positive macrophages. The assay was repeated twice on each of three biological replicates (n = 6). (a) WT Mφ; (b) WT M1-Mφ; (c) TLR2^{-/-} Mφ; (d) TLR2^{-/-} M1-Mφ; (e) TLR4^{-/-} Mφ; (f) TLR4^{-/-} M1-Mφ; (g) NOD2^{-/-} Mφ; (h) NOD2^{-/-} M1-Mφ. *, P < 0.05 compared to the corresponding unstimulated control.




FIG 3 Nitric oxide production by macrophages in response to *Porphyromonas gultae* whole cells. WT iMACs, TLR2^{-/-} iMACs, and TLR4^{-/-} iMACs (10⁵ cells) were incubated overnight with or without IFN-γ to prime the M1 macrophage phenotype or to give unprimed M0-Mφ, respectively. The unprimed and M1-primed macrophages were then incubated with viable *P. gultae* (MOI of 180:1) for 2 h and washed with DMEM containing antibiotics. *E. coli* LPS and Pam3CSK4 were used as TLR4 and TLR2 control ligands, respectively. The negative control was macrophages that were not incubated with TLR ligands or *P. gultae* cells. After 24 h, the level of nitric oxide expression was measured using the Griess reaction. The assay was repeated twice on each of three biological replicates (*n* = 6). (a) WT Mφ; (b) WT M1-Mφ; (c) TLR2^{-/-} Mφ; (d) TLR2^{-/-} M1-Mφ; (e) TLR4^{-/-} Mφ; (f) TLR4^{-/-} M1-Mφ; (g) NOD2^{-/-} Mφ; (h) NOD2^{-/-} M1-Mφ. *, *P* < 0.05 compared to the corresponding unstimulated control.

stimulating factor [G-CSF], RANTES, eotaxin, monocyte chemoattractant protein 1 [MCP-1], and macrophage inflammatory protein 1 α [MIP-1 α] were consistently secreted by M1-M ϕ after incubation with *P. gulae*, *E. coli* LPS, or Pam3CSK4 (Fig. 4 and 5). None of the TLR ligands or *P. gulae* induced the secretion of IL-2, IL-3, IL-4, IL-5, IL-9, IFN- γ , granulocyte-macrophage colony-stimulating factor (GM-CSF), or MIP-1 β from M1-M ϕ (data not shown).

The positive-control ligands *E. coli* LPS and Pam3CSK4 induced significant levels ($P < 0.01$) of IL-1 α , IL-1 β , IL-6, IL-10, IL-12p70, IL-13, IL-17, and TNF- α in M1-M ϕ compared to those in the IFN- γ -primed pre-M1-M ϕ cells (Fig. 4). The TLR2^{-/-} and TLR4^{-/-} M1-M ϕ produced the above cytokines only in response to *E. coli* LPS and Pam3CSK4, respectively, indicating that these cells were responding as expected. *P. gulae* whole cells induced significant ($P < 0.01$) levels of IL-1 α , IL-1 β , IL-6, IL-12p70, and TNF- α in M1-M ϕ compared to those in the pre-M1-M ϕ cells (Fig. 4). Of these cytokines, *P. gulae* induced very high levels of IL-1 β , IL-6, and TNF- α . There was no significant production of IL-10 or IL-17A in response to *P. gulae* in M1-M ϕ (Fig. 4). The induction of IL-6 and TNF- α secretion by *P. gulae* was completely abrogated in TLR2^{-/-} and TLR4^{-/-} M1-M ϕ cells (Fig. 4c and h). However, the secretion of IL-1 α , IL-1 β , IL-12p70, and IL-13 by M1-M ϕ cells in response to *P. gulae* was independent of either TLR2 or TLR4 expression (Fig. 4).

Similar to the production of cytokines by macrophages, various chemokines were expressed by WT M1-M ϕ in response to the control ligands. The positive-control ligands *E. coli* LPS and Pam3CSK4, in a TLR-specific manner, induced significant ($P < 0.05$) levels of eotaxin, G-CSF, KC, MCP-1, MIP-1 α , and RANTES in M1-M ϕ compared to those in the pre-M1-M ϕ cells (Fig. 5). In all cases, the deletion of either TLR2 or TLR4 resulted in a corresponding decrease in the production of chemokines in response to the corresponding control TLR ligand (Fig. 5). *P. gulae* whole cells induced significant ($P < 0.05$) levels of G-CSF, MCP-1, and MIP-1 α , but not RANTES, KC, or eotaxin, in M1-M ϕ compared to those in the pre-M1-M ϕ cells (Fig. 5). The induction of G-CSF secretion by *P. gulae* was reduced in TLR2^{-/-} and TLR4^{-/-} M1-M ϕ cells (Fig. 5b), and MCP-1 and MIP-1 α levels were reduced only in TLR4^{-/-} M1-M ϕ cells (Fig. 5d and e).

To compare the immune response induced by *P. gulae* to that induced by *E. coli*, we performed a cytokine bead array assay (Fig. 6). We observed that despite the significant NOD2, TLR2, and TLR4 responses observed in this study, the overall synthesis of TNF- α , IL-6, IL-1 β , and IL-10 induced by *P. gulae* was significantly lower than that induced by *E. coli*.

DISCUSSION

We have shown that *P. gulae* cells interact with NOD2, TLR2, and TLR4 in order to activate NF- κ B. No details have been published regarding the presence of lipopeptides/lipoproteins (TLR2 ligands) or the LPS structure (TLR4 ligand) of *P. gulae*, but given the antigenic similarities observed with *P. gingivalis*, some conclusions may be drawn. After the addition of *P. gulae* to HEK293 cells transfected with a range of TLRs and NLRs, the strongest NF- κ B response observed was through TLR2, the receptor for lipopeptides and lipoproteins (21). The TLR2 response to *P. gingivalis*, the bacterium implicated in human chronic periodontitis, is also the strongest TLR response and is considered to be essential for disease progression (22, 23). However, the *P. gingivalis* TLR2 ligand is a topic of much research (23–26). It was initially thought that the modified lipid A of *P. gingivalis* was signaling through TLR2 (25, 27, 28). However, the discovery of a copurifying lipopeptide in LPS preparations and a recent analysis of the *P. gingivalis*-induced TLR2 activity implicate lipoproteins as the main TLR2 ligand (23, 24, 26). It is possible that homologues of the lipoproteins in *P. gingivalis* are responsible for the majority of the TLR2 activity in *P. gulae*. Furthermore, it has also been shown that *P. gingivalis* fimbriae signal through TLR2 (29–31), and considering the similarities between *P. gulae* and *P. gingivalis* fimbriae (8, 9), it is possible that *P. gulae* fimbriae also contribute to this TLR2 activity.

One of the major TLR ligands in bacteria is the canonical hexa-acylated biposphorylated lipid A of the *Enterobacteriaceae* (32, 33). *P. gingivalis*, as well as other bacterial




FIG 4 Cytokine production by M1 macrophages in response to *Porphyromonas gulae* whole cells. WT iMACs, TLR2^{-/-} iMACs, and TLR4^{-/-} iMACs (10⁵ cells) were incubated overnight with IFN-γ to prime the M1 macrophage phenotype. The M1-primed macrophages were then incubated with viable *P. gulae* (MOI of 180:1) for 2 h and washed with DMEM containing antibiotics. *E. coli* LPS and Pam3CSK4 were used as TLR4 and TLR2 control ligands, respectively. The negative control was IFN-γ-primed macrophages that were not incubated with TLR ligands or *P. gulae* cells. After 24 h, the levels of cytokines in the assay supernatants were measured using a 23-plex Bioplex assay. The assay was repeated twice on each of three biological replicates (n = 6). (a) IL-1α; (b) IL-1β; (c) IL-6; (d) IL-10; (e) IL-12p70; (f) IL-13; (g) IL-17; (h) TNF-α. *, P < 0.05 compared to the corresponding negative control.




FIG 5 Chemokine production by M1 macrophages in response to *Porphyromonas gultae* whole cells. WT iMACs, TLR2^{-/-} iMACs, and TLR4^{-/-} iMACs (10⁵ cells) were incubated overnight with IFN- γ to prime the M1 macrophage phenotype. The M1-primed macrophages were then incubated with viable *P. gultae* (MOI of 180:1) for 2 h and washed with DMEM containing antibiotics. *E. coli* LPS and Pam3CSK4 were used as TLR4 and TLR2 control ligands, respectively. The negative control was IFN- γ -primed macrophages that were not incubated with TLR ligands or *P. gultae* cells. After 24 h, the levels of chemokines in the assay supernatants were measured using a 23-plex Bioplex assay. The assay was repeated twice on each of three biological replicates ($n = 6$). (a) Eotaxin; (b) G-CSF; (c) KC; (d) MCP-1; (e) MIP-1 α ; (f) RANTES. *, $P < 0.05$ compared to the corresponding negative control.

species, is able to deacylate and dephosphorylate lipid A, leading to tetra- and penta-acylated monophosphate lipid A (25, 28, 34). Both deacylation and dephosphorylation are well known to alter the immunogenicity of lipid A, with tetra-acylated lipid A being completely inert (35). The weaker TLR4 activity than TLR2 activity suggests that *P. gultae* may be able to modify its lipid A structure in a way similar to that of *P. gingivalis*. For *P. gingivalis*, this modification has been attributed to environmental regulation of deacylases and phosphatases; in particular, the presence of low iron in the growth medium has been shown to result in an altered lipid A structure (28). This has been proposed to be a mechanism by which *P. gingivalis* can escape detection of the immune system as well as dysregulate the immune response to other bacteria in the plaque biofilm (28, 36).

The NOD2 activity observed in this study indicates that peptidoglycan motifs




FIG 6 Comparison of cytokine production levels of M1 macrophages in response to *P. gultae* and *E. coli*. WT iMACs, TLR2 $^{-/-}$ iMACs, and TLR4 $^{-/-}$ iMACs (10^5 cells) were incubated overnight with IFN- γ to prime the M1 macrophage phenotype. The M1-primed macrophages were then incubated with viable *P. gultae* or *E. coli* (MOI of 180:1) for 2 h and washed with DMEM containing antibiotics. *E. coli* LPS and Pam3CSK4 were used as TLR4 and TLR2 control ligands, respectively. The negative control was IFN- γ -primed macrophages that were not incubated with TLR ligands or *P. gultae* cells. After 24 h, the levels of cytokines in the assay supernatants were measured using an 8-plex Bioplex assay. The assay was repeated twice on each of three biological replicates ($n = 6$). (a) TNF- α ; (b) IL-1 β ; (c) IL-6; (d) IL-10. *, $P < 0.05$ compared to the corresponding negative control.

(muramyl dipeptide [MDP] for NOD2) are potentially exposed on the cell surface, to an extent, or released into the medium. Given that peptidoglycan is covered by a lipid bilayer in Gram-negative bacteria and that whole cells were added to the HEK293 cells, it is possible that damage or leakage of cellular components resulted in the observed NOD2 activity. Furthermore, Gram-negative bacteria are known to secrete soluble forms of peptidoglycan, ranging in size from 20 to 200 kDa, as well as peptidoglycan subunits (37, 38). Regardless of the source, it is important to consider the influence of NOD2 ligation in interpreting results generated by use of knockout macrophages. It has been shown that *P. gingivalis* ligates both NOD1 and NOD2 in transient-transfection luciferase assays with oral epithelial cells and endothelial cells (39, 40). Although we were unable to confirm NOD1 signaling in *P. gultae*, a closely related organism, it is possible that given the low activities of the *P. gingivalis* NOD1 and NOD2 ligands observed by Okugawa et al. (39), any NOD1-ligating ability of *P. gultae* may have been below the detection threshold of the HEK-Blue NOD1 reporter cells. Experiments to investigate the activity of purified peptidoglycan from *P. gultae* in both a HEK reporter assay and immune cells are required to confirm this activity.

We have further shown that M0-M ϕ and pre-M1-M ϕ cells (primed with IFN- γ) exposed to *P. gultae* upregulate the expression of CD86 and that the subsequent M1-M ϕ cells produce nitric oxide and secrete several inflammatory cytokines, particularly IL-1 β , IL-6, and TNF- α . This indicates that the cells of the innate immune system recognize *P. gultae* and potentially target and kill the bacterium as well as initiating an adaptive immune response. The ability to stimulate macrophages to produce nitric oxide is interesting, as studies have shown that the systemic nitric oxide level is elevated in

dogs diagnosed with periodontitis (41). The source of this nitric oxide is unknown, and while there is no direct evidence that macrophages are responsible for the elevated nitric oxide, they may play some role given the results presented here. While studies of *P. gingivalis* have reported the ability to persist within macrophages, none have investigated this in “inflammatory” (M1) macrophages. We recently showed that *P. gingivalis* is unable to survive in IFN- γ -treated M1 macrophages (42), and given that we have also demonstrated that M0 “naive” macrophages produce negligible levels of nitric oxide after exposure to *P. gulae* (this study) or *P. gingivalis* (20), it is feasible that *Porphyromonas* species may be unable to persist inside activated M1-M ϕ producing large amounts of microbicidal compounds. Recent thinking on antigen presentation has elevated dendritic cells to the eminent status of antigen-presenting cells, and they undoubtedly play an important role (43, 44). However, the recent focus on dendritic cells has detracted from the role that macrophages perform as antigen-presenting cells (45). The expression of CD86 and other costimulatory molecules is essential for the engagement of T lymphocytes, with subsequent clonal selection and expansion (46). Therefore, the expression of CD86 on M1 macrophages in response to *P. gulae*, combined with nitric oxide production, indicates that these cells can play an important role in controlling infection at the infection site and can stimulate the adaptive arm of the immune system by interacting with infiltrating lymphocytes.

Inflammatory cytokines are important in establishing and maintaining a chronic inflammatory state. Exposure of pre-M1 macrophages to *P. gulae* resulted in the production of significant amounts of IL-1 β , IL-6, TNF- α , G-CSF, MCP-1, and MIP-1 α . IL-1 β , IL-6, and TNF- α are extremely important cytokines involved in the pathogenesis of human chronic periodontitis (47). Together these cytokines activate inflammatory macrophages to produce more inflammatory mediators, amplifying the immune response. TNF- α , IL-6, and IL-1 β are able to upregulate the expression of RANKL on resident gingival cells (48). This results in the differentiation of macrophages into osteoclasts, leading to resorption of the alveolar bone (49). IL-1 β and IL-6 direct the maturation of naive T cells toward a Th17 phenotype that is often observed in periodontitis (50, 51). These inflammatory cytokines also act on gingival cells, inducing the production of matrix metalloproteinases that contribute to the degradation of gingival tissue (52–54). While these are inferences based on the data accumulated from *P. gingivalis*, the similarities to the immune response shown by our data for *P. gulae* suggest that *P. gulae* may invoke a similar pathology in companion animals. The inclusion of *E. coli* whole cells in a cytokine bead array puts the immune response to *P. gulae* into some context. *E. coli* induced significantly larger amounts of the cytokines TNF- α , IL-6, and IL-1 β than those induced by *P. gulae*. It is known that *Porphyromonas* species contain penta- and tetra-acylated lipid A, whereas *E. coli* contains the more active hexa-acylated lipid A; hence, the disparity in cytokine induction may be attributable to the difference in lipid A structures. The acylation state of *P. gulae* lipid A is not yet known, and characterization of this important TLR ligand would allow further inferences to be made.

The results of the assays performed with knockout macrophages suggest that some functions of macrophages, such as nitric oxide production and CD86 expression, are very dependent on specific TLR engagement. The deletion of TLR2 but not TLR4 abolished the synthesis of nitric oxide and expression of CD86 after exposure to *P. gulae*, and the production of IL-6 and TNF- α was decreased, but not completely reduced, in the absence of either TLR2 or TLR4. This indicates that the *P. gulae* TLR4 ligand, presumably lipid A, is unable to produce nitric oxide or induce CD86 expression but is able to induce some cytokine secretion in the absence of TLR2 (lipopeptide/lipoprotein) signaling in M1-M ϕ cells. We previously showed that a preparation of *P. gingivalis* LPS was unable to induce nitric oxide production or CD86 expression in murine bone marrow-derived macrophages but was able to induce significant levels of inflammatory cytokines (20). In that study, we attributed this to TLR2-activating lipopeptides contaminating the preparation; the corroborating knockout macrophage data

in this paper suggest that TLR4 ligation, even weak ligation, may be more important for cytokine production than for nitric oxide production and CD86 expression.

The ability of macrophages to signal via NOD2 in response to *P. gulae* must also be taken into account. It is possible that signaling via NOD2 may be enough to induce the production of cytokines in the absence of TLR2, but the signal may not be strong enough to induce nitric oxide production or CD86 upregulation. Considering that NOD2 signaling recruits p38 and c-Jun N-terminal kinase (JNK) to signal through AP-1 as well as NF- κ B (31), there may be a compensatory mechanism by which cytokines can be produced in the absence of TLR2 or TLR4. Knockdown of NOD2 expression in C57/BL6 iMACs reduced the synthesis of NO and expression of CD86 in response to the positive-control ligand muramyl dipeptide. However, synthesis of NO and expression of CD86 in response to *P. gulae* cells did not appreciably decrease in the absence of NOD2 expression. Considering the strength of the TLR2 and TLR4 signals in response to most Gram-negative bacteria and the synergy that is often observed between these TLRs, it is not surprising that silencing of NOD2 did not have a significant effect on macrophage activation. However, knockout of NOD2 may result in a more substantial effect, as we were not able to completely reduce the activation of macrophages by muramyl dipeptide, suggesting that some residual NOD2 expression remained in these cells. In conclusion, we have found that *P. gulae* whole cells activate immune cells predominantly via TLR2, TLR4, and NOD2. This activation induces an M1 macrophage state after priming with IFN- γ , characterized by production of nitric oxide and upregulation of CD86. These macrophages further produce an inflammatory cytokine profile that, in a chronic disease state, would maintain inflammation in the gingival tissue. We found that the absence of TLR2 or TLR4 reduced the production of nitric oxide and CD86; however, some compensation in cytokine production was observed. Based on these results, macrophages, particularly those with inflammatory phenotypes, may play an important role in establishing and maintaining chronic inflammatory periodontal disease in companion animals.

MATERIALS AND METHODS

Growth of *Porphyromonas gulae*. *P. gulae* (ATCC 51700) obtained from the Melbourne Dental School culture collection was maintained on horse blood agar (HBA) supplemented with 10% (vol/vol) horse blood and 10 μ g/ml menadione in an MK3 anaerobic workstation (Don Whitley Scientific Limited, NSW, Australia) at 37°C, with a gas composition of 5% (vol/vol) H₂, 10% (vol/vol) CO₂ in N₂ (BOC Gases Australia, NSW, Australia). For assays, *P. gulae* was grown in Todd-Hewitt broth (THB) supplemented with hemin (10 μ g/ml), menadione (1 μ g/ml), and cysteine (500 μ g/ml) under the same culture conditions as those described above for 48 h, to an optical density at 650 nm (OD₆₅₀) of ~1.0 (late exponential growth phase). Culture purity was routinely monitored by Gram staining.

Generation of macrophage phenotypes and activation assays. Cell culture reagents were obtained from Sigma-Aldrich Pty. Ltd. (NSW, Australia) unless otherwise specified. Immortalized macrophages (derived from bone marrows of C57BL/6, TLR2^{-/-}, and TLR4^{-/-} mice) were the gift of Eicke Latz (University of Bonn, Germany). Mammalian cells were routinely grown in complete Dulbecco's minimal essential medium (DMEM), consisting of DMEM supplemented with 10% (vol/vol) fetal bovine serum (FBS), 20 mM L-glutamine, 10 mM sodium pyruvate, and 100 U-100 μ g penicillin-streptomycin. All cells were grown at 37°C in a 5% (vol/vol) CO₂ atmosphere in a Heracell 150 incubator (Thermo Fisher Scientific, NSW, Australia). Macrophages (M ϕ) were primed as previously described (20). Briefly, M ϕ cells were incubated overnight in complete DMEM supplemented with 10 ng/ml of IFN- γ (Cell Signaling Technologies, MA) to generate pre-M1-M ϕ . To activate the macrophages, the pre-M1-M ϕ or nonpolarized M0-M ϕ were then incubated with either 10 ng/ml *Escherichia coli* LPS, 10 ng/ml Pam3CSK4 (Invivogen, CA), or *P. gulae* cells (MOI of 180:1) in antibiotic-free DMEM; an MOI of 180:1 was chosen based on our previous studies, which showed this to be optimal for stimulation (11). After 2 h of incubation, the M ϕ cells were washed (twice at 400 \times g for 10 min each) in DMEM containing antibiotics and then further incubated for 16 h in complete DMEM.

To silence NOD2 expression, the plasmid psirna-mNOD2 (Invivogen) was transfected into iMACs by use of the Lipofectamine 3000 reagent according to the manufacturer's instructions. The plasmid encoding siRNA was transfected at a concentration of 250 ng per 10⁴ cells, a concentration found to be effective at reducing activation by muramyl dipeptide (MDP) while maximizing cell health.

TLR activation assay. Human embryonic kidney 293-Blue cells (HEK-Blue; Invivogen) stably transfected with NOD1, NOD2, TLR2, TLR4, TLR5, TLR7, TLR8, or TLR9 were grown in complete DMEM supplemented with Normocin (100 μ g/ml) and various combinations of Zeocin, blasticidin, and hygromycin, depending on the cell type, according to the manufacturer's (Invivogen) specifications. For assays, 2 \times 10⁴ cells (150 μ l) were seeded into each well of 96-well plates (Sigma-Aldrich), and 10-fold serial dilutions of the appropriate TLR ligand or *P. gulae* cells at various MOI were added in 50 μ l of complete

DMEM. After 20 h of incubation at 37°C in 5% (vol/vol) CO₂, 50 μl of supernatant was mixed with 150 μl of HEK-Blue detection medium (Invivogen), and the plates were incubated at 37°C until color development occurred. Developed plates were read on a Victor3 1420 multilabel counter (PerkinElmer, MA) to measure the OD₅₄₀.

Nitric oxide assay. Nitric oxide was measured using a Griess reagent kit (Life Technologies, NSW, Australia) according to the manufacturer's instructions. Briefly, the day after macrophage activation with a TLR ligand, 150 μl of the Mφ supernatant was combined with 130 μl of distilled water (dH₂O), 10 μl of *N*-(1-naphthyl)ethylenediamine dihydrochloride (1 mg/ml), and 10 μl of sulfanilic acid (1.0 mM). A standard curve was generated using 2-fold serial dilutions of a 100 μM nitrite standard solution (100 μM to 1.56 μM). The reaction was allowed to proceed for 30 min at room temperature, and then the absorbance (OD₅₅₀) was measured on a Victor3 1420 multilabel counter (PerkinElmer).

Flow cytometry analysis of surface marker expression. M0-Mφ or M1-Mφ from the activation assay were collected using a 23G syringe, washed in 2 ml phosphate-buffered saline (PBS) containing 0.1% (wt/vol) bovine serum albumin (BSA; Sigma-Aldrich) (PBS-BSA buffer), and incubated with an anti-mouse CD16/CD32 antibody (clone 2.4G2; BD Biosciences, NJ) for 20 min on ice. Cells were washed in 5 ml PBS-BSA buffer prior to incubation with a 1:1,000 dilution of anti-mouse CD86-PE-Cy7 antibody for 30 min on ice (clone GL1; BD Biosciences, NSW, Australia). Cells were washed twice in 5 ml PBS-BSA buffer and then analyzed on a model FC500 flow cytometer (Beckman Coulter, NSW, Australia). The flow cytometer was equipped with an argon ion laser operating at an excitation wavelength of 488 nm and a red solid-state diode laser operating at 635 nm. The fluorescence was measured through a 755-nm filter (PE-Cy7; FL5). The data were analyzed using FlowJo software V7.0 (Tree Star, OR). Forward and side scatter properties were used to acquire a total of 30,000 cells and to gate out the cell debris.

Cytokine bead array analysis of cell culture supernatant. Cell culture supernatants from M0-Mφ and M1-Mφ activation assays were analyzed for cytokines by using the Bioplex Pro mouse cytokine 23-plex assay (Bio-Rad Pty. Ltd., NSW, Australia). The 23-plex assay measures IL-1α, IL-1β, IL-2, IL-3, IL-4, IL-5, IL-6, IL-9, IL-10, IL-12p40, IL-12p70, IL-13, IL-17A, eotaxin, G-CSF, GM-CSF, IFN-γ, KC, MCP-1, MIP-1α, MIP-1β, RANTES, and TNF-α. The assay was performed according to the manufacturer's instructions. Briefly, 50 μl of beads was added to the assay plate and washed 2 times with 100 μl wash buffer. The samples were added in a volume of 50 μl and incubated with the beads for 1 h at room temperature with no light and constant mixing at 300 rpm on an MX4 micromixer (FinePCR, South Korea). Beads were then washed 3 times with 100 μl of wash buffer, using a Bioplex Proll wash station (Bio-Rad Pty. Ltd.), and 25 μl/well of biotinylated anti-cytokine detection antibody was added. Plates were then incubated at room temperature with no light and constant mixing at 300 rpm for 1 h. Wells were then washed 3 times with 100 μl of wash buffer, using a Bioplex Proll wash station, before bound biotin-labeled anti-cytokine antibody was detected by the addition of 25 μl of streptavidin-PE. Plates were incubated at room temperature with no light and constant mixing at 300 rpm for 10 min. Beads were then washed 3 times with 100 μl of wash buffer, using a Bioplex Proll wash station, and the beads were resuspended in 125 μl of assay buffer before reading the assay on a Bioplex 200 system (Bio-Rad Pty. Ltd.).

Statistical analysis. Data were analyzed by two-way analysis of variance (ANOVA) with the Bonferroni posttest and presented as means ± standard deviations (SD) (GraphPad Prism V5.0). Differences with *P* values of <0.05 were considered statistically significant. Unless otherwise stated, the data presented are representative of three biological replicates, each performed in duplicate (*n* = 6).

ACKNOWLEDGMENTS

This work was supported by the Australian Government, Department of Industry, Innovation and Science.

The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.

REFERENCES

1. Senhorinho GNA, Nakano V, Liu C, Song Y, Finegold SM, Avila-Campos MJ. 2011. Detection of *Porphyromonas gulae* from subgingival biofilms of dogs with and without periodontitis. *Anaerobe* 17:257–258. <https://doi.org/10.1016/j.anaerobe.2011.06.002>.
2. Oliver RC, Brown LJ. 1993. Periodontal diseases and tooth loss. *Periodontol* 2000 2:117–127. <https://doi.org/10.1111/j.1600-0757.1993.tb00224.x>.
3. Larsen J. 2010. Oral products and dental disease. *Compend Contin Educ Vet* 32:E4.
4. Dahlén G, Charalampakis G, Abrahamsson I, Bengtsson L, Falsen E. 2012. Predominant bacterial species in subgingival plaque in dogs. *J Periodont Res* 47:354–364. <https://doi.org/10.1111/j.1600-0765.2011.01440.x>.
5. Fournier D, Mouton C, Lapiere P, Kato T, Okuda K, Ménard C. 2001. *Porphyromonas gulae* sp. nov., an anaerobic, gram-negative coccobacillus from the gingival sulcus of various animal hosts. *Int J Syst Evol Microbiol* 51:1179–1189. <https://doi.org/10.1099/00207713-51-3-1179>.
6. Senhorinho GN, Nakano V, Liu C, Song Y, Finegold SM, Avila-Campos MJ. 2012. Occurrence and antimicrobial susceptibility of *Porphyromonas* spp. and *Fusobacterium* spp. in dogs with and without periodontitis. *Anaerobe* 18:381–385. <https://doi.org/10.1016/j.anaerobe.2012.04.008>.
7. Hardham J, Dreier K, Wong J, Sfintescu C, Evans RT. 2005. Pigmented-anaerobic bacteria associated with canine periodontitis. *Vet Microbiol* 106:119–128. <https://doi.org/10.1016/j.vetmic.2004.12.018>.
8. Hamada N, Takahashi Y, Watanabe K, Kumada H, Oishi Y, Umemoto T. 2008. Molecular and antigenic similarities of the fimbrial major components between *Porphyromonas gulae* and *P. gingivalis*. *Vet Microbiol* 128:108–117. <https://doi.org/10.1016/j.vetmic.2007.09.014>.
9. Oishi Y, Watanabe K, Kumada H, Ishikawa E, Hamada N. 2012. Purification and characterization of a novel secondary fimbrial protein from *Porphyromonas gulae*. *J Oral Microbiol* 4:1–7. <https://doi.org/10.3402/jom.v4i0.19076>.
10. Hajishengallis G, Darveau RP, Curtis MA. 2012. The keystone-pathogen hypothesis. *Nat Rev Microbiol* 10:717–725. <https://doi.org/10.1038/nrmicro2873>.
11. Lenzo JC, O'Brien-Simpson NM, Orth RK, Mitchell HL, Dashper SG, Reyn-

- olds EC. 2016. *Porphyromonas gulae* has virulence and immunological characteristics similar to those of the human periodontal pathogen *Porphyromonas gingivalis*. *Infect Immun* 84:2575–2585. <https://doi.org/10.1128/IAI.01500-15>.
12. Graves DT, Kang J, Andriankaja O, Wada K, Rossa C, Jr. 2012. Animal models to study host-bacteria interactions involved in periodontitis. *Front Oral Biol* 15:117–132. <https://doi.org/10.1159/000329675>.
 13. Moskow BS, Polson AM. 1991. Histologic studies on the extension of the inflammatory infiltrate in human periodontitis. *J Clin Periodontol* 18:534–542. <https://doi.org/10.1111/j.1600-051X.1991.tb00086.x>.
 14. Magnusson MK, Wick MJ. 2011. Intestinal dendritic cell and macrophage subsets: tipping the balance to Crohn's disease? *Eur J Microbiol Immunol (Bp)* 1:19–24. <https://doi.org/10.1556/EuJMI.1.2011.1.5>.
 15. Moore KJ, Sheedy FJ, Fisher EA. 2013. Macrophages in atherosclerosis: a dynamic balance. *Nat Rev Immunol* 13:709–721. <https://doi.org/10.1038/nri3520>.
 16. Akira S, Takeda K. 2004. Toll-like receptor signalling. *Nat Rev Immunol* 4:499–511. <https://doi.org/10.1038/nri1391>.
 17. Benoit M, Desnues B, Mege J-L. 2008. Macrophage polarization in bacterial infections. *J Immunol* 181:3733–3739. <https://doi.org/10.4049/jimmunol.181.6.3733>.
 18. Martinez FO, Helming L, Gordon S. 2009. Alternative activation of macrophages: an immunologic functional perspective. *Annu Rev Immunol* 27:451–483. <https://doi.org/10.1146/annurev.immunol.021908.132532>.
 19. Edwards JP, Zhang X, Frauwirth KA, Mosser DM. 2006. Biochemical and functional characterization of three activated macrophage populations. *J Leukoc Biol* 80:1298–1307. <https://doi.org/10.1189/jlb.0406249>.
 20. Holden JA, Attard TJ, Laughton KM, Mansell A, O'Brien-Simpson NM, Reynolds EC. 2014. *Porphyromonas gingivalis* lipopolysaccharide weakly activates M1 and M2 polarized mouse macrophages but induces inflammatory cytokines. *Infect Immun* 82:4190–4203. <https://doi.org/10.1128/IAI.02325-14>.
 21. Schenk M, Belisle JT. 2009. TLR2 looks at lipoproteins. *Immunity* 31:847–849. <https://doi.org/10.1016/j.immuni.2009.11.008>.
 22. Burns E, Bachrach G, Shapira L, Nussbaum G. 2006. Cutting edge: TLR2 is required for the innate response to *Porphyromonas gingivalis*: activation leads to bacterial persistence and TLR2 deficiency attenuates induced alveolar bone resorption. *J Immunol* 177:8296–8300. <https://doi.org/10.4049/jimmunol.177.12.8296>.
 23. Jain S, Coats SR, Chang AM, Darveau RP. 2013. A novel class of lipoprotein lipase-sensitive molecules mediates TLR2 activation by *Porphyromonas gingivalis*. *Infect Immun* 81:1277–1286. <https://doi.org/10.1128/IAI.01036-12>.
 24. Asai Y, Hashimoto M, Fletcher HM, Miyake K, Akira S, Ogawa T. 2005. Lipopolysaccharide preparation extracted from *Porphyromonas gingivalis* lipoprotein-deficient mutant shows a marked decrease in Toll-like receptor 2-mediated signaling. *Infect Immun* 73:2157–2163. <https://doi.org/10.1128/IAI.73.4.2157-2163.2005>.
 25. Darveau RP, Pham TT, Lemley K, Reife RA, Bainbridge BW, Coats SR, Howald WN, Way SS, Hajjar AM. 2004. *Porphyromonas gingivalis* lipopolysaccharide contains multiple lipid A species that functionally interact with both Toll-like receptors 2 and 4. *Infect Immun* 72:5041–5051. <https://doi.org/10.1128/IAI.72.9.5041-5051.2004>.
 26. Hashimoto M, Asai Y, Ogawa T. 2004. Separation and structural analysis of lipoprotein in a lipopolysaccharide preparation from *Porphyromonas gingivalis*. *Int Immunol* 16:1431–1437. <https://doi.org/10.1093/intimm/dxh146>.
 27. Kocgozlu L, Elkaim R, Tenenbaum H, Werner S. 2009. Variable cell responses to *P. gingivalis* lipopolysaccharide. *J Dent Res* 88:741–745. <https://doi.org/10.1177/0022034509341166>.
 28. Al-Qutub MN, Braham PH, Karimi-Naser LM, Liu X, Genco Ca Darveau RP. 2006. Hemin-dependent modulation of the lipid A structure of *Porphyromonas gingivalis* lipopolysaccharide. *Infect Immun* 74:4474–4485. <https://doi.org/10.1128/IAI.01924-05>.
 29. Asai Y, Ohyama Y, Gen K, Ogawa T. 2001. Bacterial fimbriae and their peptides activate human gingival epithelial cells through Toll-like receptor 2. *Infect Immun* 69:7387–7395. <https://doi.org/10.1128/IAI.69.12.7387-7395.2001>.
 30. Harokopakis E, Hajishengallis G. 2005. Integrin activation by bacterial fimbriae through a pathway involving CD14, Toll-like receptor 2, and phosphatidylinositol-3-kinase. *Eur J Immunol* 35:1201–1210. <https://doi.org/10.1002/eji.200425883>.
 31. Hsu YM, Zhang Y, You Y, Wang D, Li H, Duramad O, Qin XF, Dong C, Lin X. 2007. The adaptor protein CARD9 is required for innate immune responses to intracellular pathogens. *Nat Immunol* 8:198–205. <https://doi.org/10.1038/nri1426>.
 32. Freudenberg MA, Merlin T, Gumenscheimer M, Kalis C, Landmann R, Galanos C. 2001. Role of lipopolysaccharide susceptibility in the innate immune response to *Salmonella typhimurium* infection: LPS, a primary target for recognition of Gram-negative bacteria. *Microb Infect* 3:1213–1222. [https://doi.org/10.1016/S1286-4579\(01\)01481-2](https://doi.org/10.1016/S1286-4579(01)01481-2).
 33. Freudenberg MA, Tchaptchet S, Keck S, Fejer G, Huber M, Schütze N, Beutler B, Galanos C. 2008. Lipopolysaccharide sensing an important factor in the innate immune response to Gram-negative bacterial infections: benefits and hazards of LPS hypersensitivity. *Immunobiology* 213:193–203. <https://doi.org/10.1016/j.imbio.2007.11.008>.
 34. Sawada N, Ogawa T, Asai Y, Makimura Y, Sugiyama A. 2007. Toll-like receptor 4-dependent recognition of structurally different forms of chemically synthesized lipid A of *Porphyromonas gingivalis*. *Clin Exp Immunol* 148:529–536. <https://doi.org/10.1111/j.1365-2249.2007.03346.x>.
 35. Flad H-D, Loppnow H, Rietschel ET, Ulmer AJ. 1993. Agonists and antagonists for lipopolysaccharide-induced cytokines. *Immunobiology* 187:303–316. [https://doi.org/10.1016/S0171-2985\(11\)80346-3](https://doi.org/10.1016/S0171-2985(11)80346-3).
 36. Coats SR, Jones JW, Do CT, Braham PH, Bainbridge BW, To TT, Goodlett DR, Ernst RK, Darveau RP. 2009. Human Toll-like receptor 4 responses to *P. gingivalis* are regulated by lipid A 1- and 4'-phosphatase activities. *Cell Microbiol* 11:1587–1599. <https://doi.org/10.1111/j.1462-5822.2009.01349.x>.
 37. Horcajo P, de Pedro MA, Cava F. 2012. Peptidoglycan plasticity in bacteria: stress-induced peptidoglycan editing by noncanonical D-amino acids. *Microb Drug Resist* 18:306–313. <https://doi.org/10.1089/mdr.2012.0009>.
 38. Takada H, Uehara A. 2006. Enhancement of TLR-mediated innate immune responses by peptidoglycans through NOD signaling. *Curr Pharm Des* 12:4163–4172. <https://doi.org/10.2174/138161206778743510>.
 39. Okugawa T, Kaneko T, Yoshimura A, Silverman N, Hara Y. 2010. NOD1 and NOD2 mediate sensing of periodontal pathogens. *J Dent Res* 89:186–191. <https://doi.org/10.1177/0022034509354843>.
 40. Wan M, Liu J, Ouyang X. 2015. Nucleotide-binding oligomerization domain 1 regulates *Porphyromonas gingivalis*-induced vascular cell adhesion molecule 1 and intercellular adhesion molecule 1 expression in endothelial cells through NF-kappaB pathway. *J Periodont Res* 50:189–196. <https://doi.org/10.1111/jre.12192>.
 41. Nemeč A, Verstraete FJM, Jerin A, Šentjurc M, Kass PH, Petelin M, Pavlica Z. 2013. Periodontal disease, periodontal treatment and systemic nitric oxide in dogs. *Res Vet Sci* 94:542–544. <https://doi.org/10.1016/j.rvsc.2012.10.017>.
 42. Lam RS, O'Brien-Simpson NM, Holden JA, Lenzo JC, Fong SB, Reynolds EC. 2016. Unprimed, M1 and M2 macrophages differentially interact with *Porphyromonas gingivalis*. *PLoS One* 11:e0158629. <https://doi.org/10.1371/journal.pone.0158629>.
 43. Gordon S. 2007. The macrophage: past, present and future. *Eur J Immunol* 37(Suppl 1):S9–S17. <https://doi.org/10.1002/eji.200737638>.
 44. Cutler CW, Jotwani R. 2004. Antigen-presentation and the role of dendritic cells in periodontitis. *Periodontol* 2000 35:135–157. <https://doi.org/10.1111/j.0906-6713.2004.003560.x>.
 45. Hume DA. 2008. Macrophages as APC and the dendritic cell myth. *J Immunol* 181:5829–5835. <https://doi.org/10.4049/jimmunol.181.9.5829>.
 46. Hugues S. 2010. Dynamics of dendritic cell-T cell interactions: a role in T cell outcome. *Semin Immunol* 32:227–238. <https://doi.org/10.1007/s00281-010-0211-2>.
 47. Yucel-Lindberg T, Båge T. 2013. Inflammatory mediators in the pathogenesis of periodontitis. *Expert Rev Mol Med* 15:e7. <https://doi.org/10.1017/erm.2013.8>.
 48. Hormdeee D, Nagasawa T, Kiji M, Yashiro R, Kobayashi H, Koshy G, Noguchi K, Nitta H, Ishikawa I. 2005. Protein kinase-A-dependent osteoprotegerin production on interleukin-1 stimulation in human gingival fibroblasts is distinct from periodontal ligament fibroblasts. *Clin Exp Immunol* 142:490–497.
 49. Bartold PM, Cantley MD, Haynes DR. 2010. Mechanisms and control of pathologic bone loss in periodontitis. *Periodontol* 2000 53:55–69. <https://doi.org/10.1111/j.1600-0757.2010.00347.x>.
 50. Takahashi K, Azuma T, Motohira H, Kinane DF, Kitetsu S. 2005. The potential role of interleukin-17 in the immunopathology of periodontal disease. *J Clin Periodontol* 32:369–374. <https://doi.org/10.1111/j.1600-051X.2005.00676.x>.
 51. Vernal R, Dutzan N, Chaparro A, Puente J, Antonieta Valenzuela M, Gamonal J. 2005. Levels of interleukin-17 in gingival crevicular fluid and

- in supernatants of cellular cultures of gingival tissue from patients with chronic periodontitis. *J Clin Periodontol* 32:383–389. <https://doi.org/10.1111/j.1600-051X.2005.00684.x>.
52. Kwan Tat S, Padrines M, Théoleyre S, Heymann D, Fortun Y. 2004. IL-6, RANKL, TNF-alpha/IL-1: interrelations in bone resorption pathophysiology. *Cytokine Growth Factor Rev* 15:49–60. <https://doi.org/10.1016/j.cytogfr.2003.10.005>.
 53. Weber A, Wasiliew P, Kracht M. 2010. Interleukin-1 (IL-1) pathway. *Sci Signal* 3:cm1. <https://doi.org/10.1126/scisignal.3105cm1>.
 54. Dong W, Xiang J, Li C, Cao Z, Huang Z. 2009. Increased expression of extracellular matrix metalloproteinase inducer is associated with matrix metalloproteinase-1 and -2 in gingival tissues from patients with periodontitis. *J Periodont Res* 44:125–132. <https://doi.org/10.1111/j.1600-0765.2008.01105.x>.